There has been significant progress in the global research and development landscape of antibody therapies in the past decade.
In this review, the authors mainly from Umabs Therapeutics took advantage of Umabs Antibody Therapies Database (Umabs-DB, https://umabs.com) to provide the global landscape of approved antibody therapies.
This article shows that 162 antibody therapies have been approved by at least one regulatory agency in the world, including 122 approvals in the US, followed by 114 in Europe, 82 in Japan and 73 in China.
We believe that this article provides an insight into the trends of the global development of antibody therapies. The two co-corresponding authors are Dr. Hongyu Zhang and Dr. Bo Liu.